Market Research Logo

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
    • The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
    • The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Wet (Neovascular / Exudative) Macular Degeneration Overview
    Therapeutics Development
    Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview
    Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies
    Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development
    Aciont Inc.
    Adverum Biotechnologies, Inc.
    Allergan Plc
    Alteogen Inc.
    Amakem NV
    Ampio Pharmaceuticals, Inc.
    Apellis Pharmaceuticals, Inc.
    Apexigen, Inc.
    Applied Genetic Technologies Corporation
    Benitec Biopharma Limited
    Boehringer Ingelheim GmbH
    Cell Medica Limited
    Charlesson LLC.
    Cipla Ltd.
    Clanotech AB
    Clearside BioMedical, Inc.
    Clonz Biotech Private Limited
    Coherus BioSciences, Inc.
    Daiichi Sankyo Company, Limited
    Diffusion Pharmaceuticals Inc.
    Eleven Biotherapeutics Inc.
    Exonate Limited
    F. Hoffmann-La Roche Ltd.
    Formycon AG
    Graybug Vision Inc
    GTx, Inc.
    iCo Therapeutics Inc.
    Icon Bioscience, Inc.
    Iconic Therapeutics, Inc.
    Kala Pharmaceuticals, Inc.
    Kodiak Sciences Inc.
    Mabion SA
    MeiraGTx Limited
    Mitotech S.A.
    Ocular Therapeutix, Inc.
    Ohr Pharmaceutical Inc.
    Ophthotech Corp.
    Oxford BioMedica Plc
    PanOptica, Inc.
    Pfenex Inc.
    Pfizer Inc.
    pSivida Corp.
    Regeneron Pharmaceuticals Inc
    RegenxBio Inc.
    RXi Pharmaceuticals Corporation
    Santen Pharmaceutical Co., Ltd.
    Sanwa Kagaku Kenkyusho Co., Ltd.
    TRACON Pharmaceuticals, Inc.
    TWi Pharmaceuticals, Inc.
    Tyrogenex, Inc.
    Xbrane Biopharma AB
    Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (aflibercept + nesvacumab) - Drug Profile
    (aflibercept + rinucumab) - Drug Profile
    A-006 - Drug Profile
    abicipar pegol - Drug Profile
    AC-301 - Drug Profile
    ACX-107 - Drug Profile
    aflibercept - Drug Profile
    aflibercept biosimilar - Drug Profile
    aflibercept biosimilar - Drug Profile
    AGN-151200 - Drug Profile
    ALG-1001 - Drug Profile
    AMA-0428 - Drug Profile
    APL-2 - Drug Profile
    APX-003 - Drug Profile
    APX-3330 - Drug Profile
    AVA-101 - Drug Profile
    AVA-201 - Drug Profile
    avacincaptad pegol sodium - Drug Profile
    axitinib - Drug Profile
    AXT-108 - Drug Profile
    bertilimumab - Drug Profile
    Beta-LGND2 - Drug Profile
    BI-144807 - Drug Profile
    brolucizumab - Drug Profile
    C-16Y - Drug Profile
    CBT-128 - Drug Profile
    CLT-005 - Drug Profile
    CLT-28643 - Drug Profile
    cyclosporine - Drug Profile
    DA-3131 - Drug Profile
    danazol - Drug Profile
    DE-120 - Drug Profile
    DNX-214 - Drug Profile
    Doxarubicin Pegylated - Drug Profile
    Drug for Age Related Macular Degeneration - Drug Profile
    DS-7080 - Drug Profile
    ENV-1305 - Drug Profile
    GB-101 - Drug Profile
    Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile
    Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile
    hI-con1 - Drug Profile
    IVMED-50 - Drug Profile
    IVMED-55 - Drug Profile
    K-106 - Drug Profile
    KSI-201 - Drug Profile
    LHA-510 - Drug Profile
    Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    OCU-200 - Drug Profile
    OLX-301 - Drug Profile
    ONL-1204 - Drug Profile
    OPT-302 - Drug Profile
    OXB-201 - Drug Profile
    PAN-90806 - Drug Profile
    pegpleranib sodium - Drug Profile
    PF-05206388 - Drug Profile
    PF-655 - Drug Profile
    plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    ranibizumab - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    ranibizumab biosimilar - Drug Profile
    Recombinant Protein for Age Related Macular Degeneration - Drug Profile
    Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    RES-529 - Drug Profile
    RG-7716 - Drug Profile
    RGX-314 - Drug Profile
    RXI-109 - Drug Profile
    SK-1011 - Drug Profile
    Small Molecule for Wet AMD and Dry AMD - Drug Profile
    Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile
    Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile
    SPHINX-31 - Drug Profile
    squalamine lactate - Drug Profile
    sunitinib malate - Drug Profile
    Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile
    TRC-105 - Drug Profile
    triamcinolone acetonide - Drug Profile
    TT-211 - Drug Profile
    TT-231 - Drug Profile
    X-82 - Drug Profile
    Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects
    Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products
    Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Development by Companies, H2 2016 (Contd..5)
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alteogen Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cell Medica Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cipla Ltd., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..3), H2 2016
    Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report